Baxter International shares plunged 14.5% to log their worst day in three months after the firm cut its 2025 EPS and sales outlook and reduced its dividend to repay debt. While Q3 profit rose 41%, margins fell sharply due to higher manufacturing costs and weak IV solution demand. Shipment delays and soft US hospital orders add to near-term pressure.